Cognitive Neurostim Devices: Promises, Unknowns Explored At FDA Workshop
This article was originally published in The Gray Sheet
Executive Summary
Noninvasive electromagnetic neurostimulation devices designed to improve peoples’ memory or learning abilities currently show some promise, but also feature unknowns surrounding their mechanisms of actions and long term effects, said speakers at an FDA workshop on the devices.
You may also be interested in...
Neuronetics Launches Major Registry To Track NeuroStar TMS Outcomes
The registry will collect data from more than 6,000 depression patients treated with transcranial magnetic stimulation at more than 100 different treatment facilities in the US to better understand how the therapy benefits patients in the "real world."
Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker